Abstract
BackgroundThe aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC).MethodsTumor response, progression-free survival (PFS), and overall survival(OS) were retrospectively evaluated in consecutive patients with unresectable HCC who received TACE with or without H101 between April 2012 and April 2013.ResultsPatients with unresectable HCC were treated with transarterial injection of H101 with TACE (H101 group, n = 87) or TACE alone (control group, n = 88). Clinicopathological features were similar between the groups. Treatment response was significantly different between the groups (P = 0.01). In the H101 group, 25 patients demonstrated a complete response (CR, 28.7 %); 28 patients, a partial response (PR, 32.2 %); 23 patients, stable disease (SD, 26.4 %); and 11 patients, progressive disease (PD, 12.6 %). In the control group, 13 patients demonstrated CR (14.8 %); 19, PR (21.6 %); 34, SD (38.6 %); and 22, PD (25 %). OS and PFS was also significantly different between the groups. In the H101 group, median OS and PFS were 12.8 and 10.49 months, whereas in the control group they were 11.6 and 9.72 months, respectively (OS: P = 0.046; PFS: P = 0.044).ConclusionIn patients with unresectable HCC, H101 combined with TACE improves OS, PFS and treatment response compared with TACE alone.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1715-x) contains supplementary material, which is available to authorized users.
Highlights
The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC)
The Recombinant human adenovirus type 5 (H101) virus produced by Shanghai Sunway Biotech contains a deletion of a 78.3–85.8 μm gene segment in the E3 region
From April 2012 to April 2013, 187 patients with unresectable Hepatocellular carcinoma (HCC) were treated with TACE plus H101 met the inclusion criteria (H101 group) (Additional file 1: Figure S1)
Summary
The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC). Especially oncolytic viral therapy, is a promising treatment for liver tumors and is being increasingly used in the clinic with favorable results [4]. H101 is a recombinant human type-5 adenovirus (Ad5) in which the gene encoding the 55 kDa E1B protein responsible for p53-binding and inactivation has been deleted to confer p53-selective replication of oncolytic viruses inducing accumulation of p53 leading to direct and selective. The E3 region is responsible for the inhibition of host immunity, which enhances virus replication and spread in tumor cells [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
